ETF Series Solutions Trust Range Cancer Therapeutics ETF
CNCR
CNCR was delisted on the 27th of May, 2025.
23 hedge funds and large institutions have $20.9M invested in ETF Series Solutions Trust Range Cancer Therapeutics ETF in 2018 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 6 increasing their positions, 9 reducing their positions, and 3 closing their positions.
68% more capital invested
Capital invested by funds: $12.5M → $20.9M (+$8.49M)
0% more funds holding
Funds holding: 23 → 23 (0)
0% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 3
2.96% less ownership
Funds ownership: 22.3% → 19.34% (-3%)
33% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
+$456K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$418K |
| 3 |
LPL Financial
San Diego,
California
|
+$397K |
| 4 |
PAG
Private Advisor Group
Morristown,
New Jersey
|
+$84.4K |
| 5 |
OC
Oppenheimer & Co
New York
|
+$44.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BL
BCWM LLC
Overland Park,
Kansas
|
-$2.1M |
| 2 |
Morgan Stanley
New York
|
-$930K |
| 3 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$383K |
| 4 |
CIA
Choate Investment Advisors
Boston,
Massachusetts
|
-$224K |
| 5 |
Commonwealth Equity Services
Waltham,
Massachusetts
|
-$86.9K |
CNCR Hedge Fund Activity: Q4 2018 in Review
23 of the 4,489 institutional investors tracked by Wall St. Rank reported a position in ETF Series Solutions Trust Range Cancer Therapeutics ETF (CNCR) for Q4 2018, worth a combined $20.9M — up 68% from $12.5M a quarter earlier.
Fund positioning in CNCR was balanced in Q4 2018: 3 funds opened new positions, 3 closed out, 6 added to existing stakes and 9 trimmed.
The largest buyer was Jane Street, adding an estimated $456K. The largest seller was BCWM LLC, cutting an estimated $2.1M.
- 23 institutional investors held ETF Series Solutions Trust Range Cancer Therapeutics ETF (CNCR) as of Q4 2018, unchanged from Q3 2018.
- Funds reported $20.9M of ETF Series Solutions Trust Range Cancer Therapeutics ETF stock for Q4 2018, up 68% quarter-over-quarter.
- 3 funds opened new ETF Series Solutions Trust Range Cancer Therapeutics ETF positions in Q4 2018 and 3 closed out, a net change of 0 holders.
- The largest ETF Series Solutions Trust Range Cancer Therapeutics ETF buyer in Q4 2018 was Jane Street, an estimated $456K added.
- The largest ETF Series Solutions Trust Range Cancer Therapeutics ETF seller in Q4 2018 was BCWM LLC, an estimated $2.1M sold.
Based on aggregated 13F filings for Q4 2018.